Last reviewed · How we verify
Biological: Fecal Microbiota Transplantation
Biological: Fecal Microbiota Transplantation is a Biologic drug developed by Fundación GECP. It is currently in Phase 2 development for Clostridioides difficile infection, Inflammatory bowel disease, Irritable bowel syndrome.
Fecal Microbiota Transplantation involves transferring fecal matter from a healthy donor into a patient's gut to restore a balanced gut microbiome.
Fecal Microbiota Transplantation involves transferring fecal matter from a healthy donor into a patient's gut to restore a balanced gut microbiome. Used for Clostridioides difficile infection, Inflammatory bowel disease, Irritable bowel syndrome.
At a glance
| Generic name | Biological: Fecal Microbiota Transplantation |
|---|---|
| Sponsor | Fundación GECP |
| Modality | Biologic |
| Therapeutic area | Gastroenterology |
| Phase | Phase 2 |
Mechanism of action
This process aims to treat various gastrointestinal disorders by introducing beneficial bacteria and other microorganisms into the patient's gut. The exact mechanisms of action are not fully understood, but it is believed to involve the restoration of a healthy gut microbiome, which can help to regulate the immune system and improve overall health.
Approved indications
- Clostridioides difficile infection
- Inflammatory bowel disease
- Irritable bowel syndrome
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
Key clinical trials
- Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis (PHASE3)
- Effect of Oral Microbiota on MDRO Decolonization (PHASE1, PHASE2)
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Nationality in the Treatment of IBD (NA)
- Fecal Microbiota Transplant (PHASE4)
- Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder. (PHASE1, PHASE2)
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients (PHASE1)
- Fecal Microbial Transplants for the Treatment of Pancreatic Cancer (EARLY_PHASE1)
- Transfer of Feces in Ulcerative Colitis 2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: Fecal Microbiota Transplantation CI brief — competitive landscape report
- Biological: Fecal Microbiota Transplantation updates RSS · CI watch RSS
- Fundación GECP portfolio CI
Frequently asked questions about Biological: Fecal Microbiota Transplantation
What is Biological: Fecal Microbiota Transplantation?
How does Biological: Fecal Microbiota Transplantation work?
What is Biological: Fecal Microbiota Transplantation used for?
Who makes Biological: Fecal Microbiota Transplantation?
What development phase is Biological: Fecal Microbiota Transplantation in?
What are the side effects of Biological: Fecal Microbiota Transplantation?
Related
- Manufacturer: Fundación GECP — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Clostridioides difficile infection
- Indication: Drugs for Inflammatory bowel disease
- Indication: Drugs for Irritable bowel syndrome
- Compare: Biological: Fecal Microbiota Transplantation vs similar drugs
- Pricing: Biological: Fecal Microbiota Transplantation cost, discount & access